Opko Health Inc (OPK) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.016x

Based on the latest financial reports, Opko Health Inc (OPK) has a cash flow conversion efficiency ratio of -0.016x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.31 Million) by net assets ($1.20 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Opko Health Inc's balance sheet to measure how much of total assets are equity-financed.

Opko Health Inc - Cash Flow Conversion Efficiency Trend (1995–2025)

This chart illustrates how Opko Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Opko Health Inc (OPK) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Opko Health Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Opko Health Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
V2 Retail Limited
NSE:V2RETAIL
0.122x
Synsam AB
ST:SYNSAM
0.144x
Winnebago Industries Inc
NYSE:WGO
-0.020x
Cangzhou Dahua Co Ltd
SHG:600230
0.018x
Gryphon Capital Income Trust
AU:GCI
-0.161x
Suncrete, Inc. Class A Common Stock
NASDAQ:RMIX
-1.040x
Changchun Zhiyuan New Energy Equipment Co. Ltd
SHE:300985
0.128x
Silicon Integrated Systems Corp
TW:2363
-0.001x

Annual Cash Flow Conversion Efficiency for Opko Health Inc (1995–2025)

The table below shows the annual cash flow conversion efficiency of Opko Health Inc from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see Opko Health Inc market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $1.27 Billion $-178.54 Million -0.141x -4.79%
2024-12-31 $1.37 Billion $-183.49 Million -0.134x -562.07%
2023-12-31 $1.39 Billion $-28.20 Million -0.020x +66.70%
2022-12-31 $1.56 Billion $-95.19 Million -0.061x -367.93%
2021-12-31 $1.69 Billion $38.34 Million 0.023x -3.67%
2020-12-31 $1.67 Billion $39.48 Million 0.024x +122.10%
2019-12-31 $1.61 Billion $-172.52 Million -0.107x -75.35%
2018-12-31 $1.79 Billion $-109.14 Million -0.061x -21.99%
2017-12-31 $1.84 Billion $-92.08 Million -0.050x -426.02%
2016-12-31 $2.09 Billion $32.05 Million 0.015x -81.51%
2015-12-31 $1.98 Billion $164.02 Million 0.083x +176.62%
2014-12-31 $835.80 Million $-90.38 Million -0.108x -62.22%
2013-12-31 $872.98 Million $-58.19 Million -0.067x +46.68%
2012-12-31 $203.28 Million $-25.41 Million -0.125x -8.73%
2011-12-31 $160.88 Million $-18.50 Million -0.115x +86.12%
2010-12-31 $23.05 Million $-19.09 Million -0.828x -104.90%
2009-12-31 $57.73 Million $-23.34 Million -0.404x +99.50%
2008-12-31 $359.00K $-29.29 Million -81.599x -7980.45%
2007-12-31 $16.78 Million $-16.95 Million -1.010x -2574.56%
2006-12-31 $8.08 Million $-305.00K -0.038x +63.28%
2005-12-31 $8.72 Million $-897.00K -0.103x +36.41%
2004-12-31 $9.83 Million $-1.59 Million -0.162x +71.45%
2003-12-31 $10.30 Million $-5.84 Million -0.566x -3.00%
2002-12-31 $16.07 Million $-8.84 Million -0.550x -79.44%
2001-12-31 $26.12 Million $-8.01 Million -0.306x -119.84%
2000-12-31 $35.77 Million $-4.99 Million -0.139x +88.80%
1999-12-31 $2.59 Million $-3.23 Million -1.245x -216.43%
1998-12-31 $6.10 Million $-2.40 Million -0.393x +85.08%
1997-12-31 $1.10 Million $-2.90 Million -2.636x -142.55%
1996-12-31 $2.30 Million $-2.50 Million -1.087x -171.74%
1995-12-31 $5.00 Million $-2.00 Million -0.400x --

About Opko Health Inc

NASDAQ:OPK USA Diagnostics & Research
Market Cap
$996.72 Million
Market Cap Rank
#9546 Global
#2617 in USA
Share Price
$1.32
Change (1 day)
-2.22%
52-Week Range
$1.10 - $1.65
All Time High
$11.91
About

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigen… Read more